**Research letter**

**Myocarditis and Sudden Cardiac Death in the Community: Clinical and Pathological Insights From a National Registry in the United Kingdom**

Raghav T. Bhatia\* a, b MBBS, MRCP,Gherardo Finocchiaro\* a MD, PhD, Joseph Westaby a,c MBBS, Nikhil Chatrath a MBBS, MRCP,Elijah R. Behr a MA, MBBS, MD, FRCP, Michael Papadakis a MBBS, MD, FRCP, Sanjay Sharma a BSc, MBChB, MD, FRCP, Mary N. Sheppard a, c MBBCH, BAO, BSc, MD, FRCPath

**Institutions:**

a Cardiovascular Clinical Academic Group and Cardiology Research Centre, St. George's, University of London, St. George's University Hospitals NHS Foundation Trust, United Kingdom

b Hull University Teaching Hospitals NHS Trust, Kingston-upon-Hull, United Kingdom c Cardiovascular Pathology Department, St George's, University of London, London, United Kingdom

\*Contributed equally as first authors

Current word count: 777 words

**Author for correspondence:**

Professor Mary N Sheppard,

Professor of Cardiovascular Pathology, St. George’s University of London, Cardiovascular Sciences, Cranmer Terrace, London, SW17 0RE, UK.

E-mail: [m.sheppard@sgul.ac.uk](mailto:m.sheppard@sgul.ac.uk)

**Keywords:** Community, myocarditis, prevention, sudden cardiac death.

**Disclosures**: No author has any relevant conflicts of interest to declare.

Myocarditis is an inflammatory cardiac disorder with variable clinical presentations and outcomes.1,2 Whereas some patients present with transient symptoms followed by rapid resolution, others may develop cardiogenic shock or fatal arrhythmias. A significant proportion of patients die in the community and are diagnosed at autopsy1–3, raising questions about missed opportunities of a timely diagnosis for appropriate intervention to mitigate the risk of sudden cardiac death (SCD). We aimed to examine the presenting features, and circumstances of death in a large cohort of decedents who experienced SCD in the community and were subsequently diagnosed with myocarditis at autopsy.

We reviewed 7702 consecutive cases of SCD referred to our specialist cardiac pathology centre between 1994 and 2022. SCD was defined as death from a cardiovascular (CV) cause within 12-hours of apparent well-being. Clinical information was obtained from referring coroners, and included, demographic characteristics of the deceased, medical history, family history and circumstances of death. Cases underwent comprehensive autopsy evaluation of the heart, including histological analysis of a minimum of 10-tissue blocks, by expert cardiac pathologists (JW and MNS).4 The diagnosis of myocarditis was based upon published histological criteria.5 Ethical approval was granted for this study (10/H0724/38). The data that support the findings of this study are available from the corresponding author upon reasonable request. Results are expressed as mean±SD for continuous variables, or as number of cases and percentage for categorical variables. Comparison between variables was performed using two sample t-test or Fisher's exact test.

We only included deaths attributed to myocarditis in non-hospitalised individuals. Of the total cases of SCD, 82 (1.1%) were attributed to myocarditis. The majority of decedents were male (n=53 [65%]) with a mean age of death 32±15 years (range 1-68 years). The mean heart weight was 378±128 g. Most individuals died at rest (n=73 [89%]), including during sleep (n=16 [19%]) whilst the remainder died during exertion (n=9 [11%]). Our cohort comprised 5 athletes, (3 of whom died at rest, and 2 during exertion). Only 1 individual was diagnosed with viral myocarditis, antemortem.

Most individuals (n=50 [61%]) were reportedly asymptomatic prior to SCD. Thirteen (16%) individuals reported symptoms consistent with an infective process in the 6-months prior to death. CV symptoms were reported in 15 (18%) decedents, including dyspnoea n=6 [7%]), chest pain (n=5 [6%]), syncope (n=3 [4%]) and palpitation (n=1 [1%]). Four decedents (5%) reported co-existing CV symptoms in the context of ongoing infective symptoms. Lymphocytic myocarditis was the most common form, n=46 (56%); followed by, neutrophilic, n=14 (17%), eosinophilic, n=13 (16%), toxic, n=6 (7%), and giant cell myocarditis, n=3 (4%). There were no significant differences in the clinical or histopathological findings between individuals who died at rest compared with individuals who died during activity.

Our observations show that myocarditis is a relatively rare cause of SCD in non-hospitalised individuals (1.1%) and the majority of decedents die at rest. Lymphocytic myocarditis was the most common form, which is consistent with data from studies based on living individuals assessed with endomyocardial biopsies (EMB).1,2,5 Almost 1 in 5 individuals had prodromal cardiac symptoms, however only 26% of these occurred in the context of an infective process. According to our results, only 5% of the decedents would have had a suspected diagnosis of myocarditis on the basis of cardiac symptoms in conjunction with an infective process, prior to SCD. Our findings highlight the challenges in identifying non acute cases of an arrhythmogenic substrate in the community and emphasise the need for early diagnosis which may be facilitated by a high index of suspicion of the disease and instigating rapid assessment and risk-stratification to reduce morbidity and mortality.

Our study has some limitations. Our referral centre for cardiac pathology is more likely to receive hearts from subjects where the clinical history is suggestive of an inherited cardiac disease, or the autopsy findings are normal or equivocal, hence our data may have underestimated the prevalence of SCD from myocarditis in non-hospitalised individuals. Nevertheless, we receive a high volume of unexpected SCD referrals (>400/year) and the large number of examinations performed in our unit suggests that the results are likely to represent the type and frequency of cardiac diseases implicated in SCD, especially in young individuals.

In conclusion, myocarditis accounts for 1% of all SCDs in non-hospitalised individuals. Cardiac symptoms preceding a fatality are noted in approximately one in five individuals although only 5% express cardiac symptoms in conjunction with infective symptoms.

**Acknowledgments:** We thank Cardiac Risk in the Young (CRY), which fund and support the CRY Cardiovascular Pathology Unit.

**Funding Sources**: R.T.B., N.C., and G.F. are funded by a research grant from Cardiac Risk in the Young.

**Disclosures**: No author has any relevant conflicts of interest to declare.

**References:**

1. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2013;34(33):2636-2648. doi:10.1093/eurheartj/eht210

2. Harris KM, Mackey-Bojack S, Bennett M, Nwaudo D, Duncanson E, Maron BJ. Sudden Unexpected Death Due to Myocarditis in Young People, Including Athletes. *Am J Cardiol*. 2021;143:131-134. doi:10.1016/j.amjcard.2020.12.028

3. Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac death caused by myocarditis in persons aged 1-49 years: a nationwide study of 14 294 deaths in Denmark. *Forensic Sci Res*. 2019;4(3):247-256. doi:10.1080/20961790.2019.1595352

4. Basso C, Aguilera B, Banner J, et al. Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology. *Virchows Archiv*. 2017;471(6). doi:10.1007/s00428-017-2221-0

5. Mary N. Sheppard. *Practical Cardiovascular Pathology*. 3rd ed. CRC Press; 2022.

**Figure 1: Study overview**

Macroscopic (A) and microscopic appearances (B) of myocardium with lymphocytic myocarditis. The myocardium demonstrates mottling with dark discolouration (A) and evidence of a diffuse lymphoid infiltrate with corresponding myocyte necrosis (B). CV: cardiovascular; n= number of cases; SCD: sudden cardiac death